Flualprazolam

Flualprazolam enhances GABAergic inhibition in brainstem respiratory centres, reducing respiratory rate and tidal volume. In patients with pre-existing severe respiratory insufficiency, this depression may be life-threatening. Respiratory depression was documented in clinical cases (Blumenberg et al. 2020).

Benzodiazepines depress central respiratory drive and reduce upper airway muscle tone, exacerbating both central and obstructive sleep apnoea. The sedative and muscle-relaxant effects of flualprazolam would be expected to increase apnoea severity, duration, and associated hypoxaemia.

Benzodiazepines produce skeletal muscle relaxation through spinal and supraspinal GABA-A potentiation. In patients with myasthenia gravis, this additional muscle relaxant effect may critically worsen neuromuscular weakness, particularly affecting respiratory muscles.

Benzodiazepines carry inherent reinforcing properties via mesolimbic reward pathway activation. Flualprazolam's sub-milligram potency and rapid onset increase abuse liability. Compulsive redosing is a documented risk, exacerbated by amnestic effects causing users to forget prior doses.

Flualprazolam is primarily metabolised by CYP3A4 (Wagmann et al. 2020). Hepatic impairment reduces CYP3A4 activity, decreasing clearance and increasing systemic exposure. Given flualprazolam's already extended half-life (approximately double alprazolam's in rats), accumulation risk in hepatic impairment is significant.

Ketoconazole, itraconazole, clarithromycin, erythromycin, HIV protease inhibitors, and grapefruit juice inhibit CYP3A4, the primary enzyme responsible for flualprazolam biotransformation (Wagmann et al. 2020). Even moderate inhibition could produce disproportionate increases in exposure since CYP3A4 represents the dominant elimination pathway.

Benzodiazepines as a class carry teratogenicity risk, including increased incidence of cleft palate in some epidemiological studies. Neonatal withdrawal syndrome is documented with maternal benzodiazepine use. No reproductive toxicity data specific to flualprazolam exist.

Elderly individuals have increased sensitivity to benzodiazepine-induced CNS depression, reduced CYP3A4 activity leading to prolonged elimination, and elevated risk of falls and fractures from motor control impairment. Flualprazolam's extended half-life compounds accumulation risk in this population.

Opioids were co-detected in 83% of flualprazolam-associated postmortem cases (Papsun et al. 2021), with fentanyl the most common co-drug. The synergistic CNS and respiratory depression from benzodiazepine-opioid combinations is the primary mechanism of flualprazolam-associated death. This combination should be considered an absolute contraindication.

Alcohol potentiates GABA-A receptor activity through a distinct binding site, producing additive-to-synergistic CNS depression when combined with benzodiazepines. The UK ACMD advisory specifically identified increased risk of unconsciousness and respiratory depression when flualprazolam is combined with alcohol or other sedatives.

Benzodiazepines may possess weak anticholinergic activity that can precipitate acute angle-closure in patients with narrow anterior chamber angles. This is a standard class contraindication listed in alprazolam prescribing information.